1-methyl-3-hydroxypyridine-2-one has been researched along with 2,3-dihydroxypyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, SM; Fullagar, JL; Jacobsen, JA; Miller, MT | 1 |
| Kornacki, JR; Mrksich, M; Oyelere, AK; Patil, V; Sodji, QH | 1 |
2 other study(ies) available for 1-methyl-3-hydroxypyridine-2-one and 2,3-dihydroxypyridine
| Article | Year |
|---|---|
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
Topics: Antigens, Bacterial; Bacterial Toxins; Chelating Agents; Copper; Drug Design; Humans; Hydroxyquinolines; Iron; Ligands; Lipoxygenase Inhibitors; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Monophenol Monooxygenase; Nitric Oxide Synthase Type II; Recombinant Proteins; Small Molecule Libraries; Structure-Activity Relationship; Sulfonamides; Zinc | 2011 |
3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Intracellular Space; Molecular Docking Simulation; Protein Conformation; Pyridines; Pyridones; Structure-Activity Relationship; Substrate Specificity; Thiones; Zinc | 2013 |